51st week of 2009 patent applcation highlights part 45 |
Patent application number | Title | Published |
20090312223 | Method of Controlling Structure and Rheology of Low Active Liquid Cleansers by Selecting Perfume Components - The invention relates to method of enhancing viscosity of low active liquid cleanser by adding perfumes individual perfume components or mixtures of components. | 2009-12-17 |
20090312224 | Method of Reducing Viscosity of Concentrated Liquid Cleansers by Selection of Perfume Components - The invention relates to method of reducing viscosity of high active liquid concentrate cleanser by adding perfumes, individual perfume components, or mixtures of components. | 2009-12-17 |
20090312225 | Light Duty Liquid Cleaning Compositions and Methods of Manufacture and Use Thereof - The invention encompasses liquid cleaning compositions, for example, dish washing liquids, and methods of their manufacture and use, which possess enhanced cleaning ability. The cleaning compositions of the invention include acidic light duty liquid cleaning compositions with low toxicity and antibacterial efficacy on surfaces, for example, hard surfaces. | 2009-12-17 |
20090312226 | Light Duty Liquid Cleaning Compositions And Methods Of Manufacture And Use Thereof - The invention encompasses liquid cleaning compositions, for example, dish washing liquids, and methods of their manufacture and use, which possess enhanced cleaning ability. The cleaning compositions of the invention include acidic light duty liquid cleaning compositions with low toxicity and antibacterial efficacy on surfaces, for example, hard surfaces. | 2009-12-17 |
20090312227 | LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF - The invention encompasses liquid cleaning compositions, for example, dish washing liquids, and methods of their manufacture and use, which possess enhanced cleaning ability. The cleaning compositions of the invention include acidic light duty liquid cleaning compositions with low toxicity and antibacterial efficacy on surfaces, for example, hard surfaces. | 2009-12-17 |
20090312228 | AQUEOUS CLEANING CONCENTRATES - A highly concentrated aqueous cleaning solution which is stable in concentrated and diluted form and is effective upon dilution with water having a water hardness level of 0-350 ppm comprises 10-30 wt. % water, a chelating agent, an aminoalkanol solvent, at least one surfactant, and optionally, an organic alcohol or glycol ether solvent. | 2009-12-17 |
20090312229 | Method and device for manufacturing materials from hydrophobic hollow natural fibres, and use thereof - The invention relates to a method for processing hydrophobic hollow natural fibres, in particular vegetable hollow natural fibres and more particularly kapok fibres, to form material, and to a material obtainable by such a method. The invention furthermore relates to “the use of such aτnaterial as absorption medium for apolar substances and a device for performing the method. | 2009-12-17 |
20090312230 | PERFUME TESTERS OR PERFUMES - The invention relates to a granule, perfume tester or perfume, a method for making such a granule, tester or perfume and use thereof. The perfume tester or perfume according to the invention is characterised in that it comprises a granule ( | 2009-12-17 |
20090312231 | 1-Aza-3,7-Dioxabicyclo[3,3,0]Octane Compounds and Monocyclic Oxazolidines as Pro-Fragrances - Silicic acid esters to which fragrances are bound, preferably as 1-aza-3,7-dioxabicyclo[3,3,0]octane compounds or as monocyclic oxazolidines and that are suitable for adding fragrance to detergents and cleaning agents because they release the bound fragrances in hydrolysis. | 2009-12-17 |
20090312232 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312233 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312234 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312235 | Method for producing insulin in the form of an oral preparation - The invention belongs to pharmacology and medicine, particularly, to endocrinology. | 2009-12-17 |
20090312236 | PEGYLATED INSULIN LISPRO COMPOUNDS - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 2009-12-17 |
20090312237 | REGULATING FAT AND CARBOHYDRATE OXIDATION IN MUSCLE TISSUE COMPRISING CONTROLLING GARNITINE CONTENT IN MUSCLE - Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat oxidation, and particularly increasing the level of fat oxidation in accordance with the present invention, by providing substances compositions and methodologies in accordance with the present invention, enable medicaments to be manufactured and methodologies employed that find use in the treatment of disorders and conditions of the human and/or animal body caused by impairment of the usual level of fat oxidation, including obesity and type 2 diabetes. | 2009-12-17 |
20090312238 | Protection Against Oxidative Damage in Cells - The present invention relates to the use of MT as a reducing system for the Msr enzymes and other oxioreductase enzymes which form similar intermediates. Specifically, the invention provides for a reduction in the level of oxidative damage in cells through an increase in levels of MT by administration of suitable compounds, resulting in an increase in the activity of the Msr enzymes. | 2009-12-17 |
20090312239 | PREPARATION, FOR USE, IN PARTICULAR, FOR TISSUE AUGMENTATION AND HEALING - The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrisation agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation comprises oxidized cellulose, the latter is present in a proportion greater than that of the said globin material, which in that case is a natural or modified globin material which is insoluble at physiological pH; and the use of this preparation, more particularly for filling or cicatrisation. | 2009-12-17 |
20090312240 | Synthesis of Sialic Acid in Plants - A method of synthesizing sialic acid in plants, and plants capable of synthesizing sialic acid is provided. Furthermore, a method of producing sialylated a protein in a plant is also provided. The method to synthesize sialic acid comprises providing a plant comprising a nucleotide sequence encoding N-acetyl neuraminic acid (Neu5Ac) synthase or Neu5Ac lyase, and expressing the nucleotide sequence thereby synthesizing sialic acid. The plant may also co-express a nucleotide sequence encoding one or more than one of an epimerase, a CMP-Neu5 Ac synthase, CMP-Neu5Ac transporter and a sialyltransferase. | 2009-12-17 |
20090312241 | Macrocyclic Compounds as Antiviral Agents - The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R | 2009-12-17 |
20090312243 | TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) WITH ANTI-ANGIOGENIC COMPOUNDS - Inhibitors of angiogenesis are disclosed as being useful therapeutics for treating various aspects of inflammatory bowel disease, in particular Crohn's Disease. A method for decreasing the magnitude of intestinal inflammation or inflammatory infiltrate in bowel tissue, a method for lowering systemic or gut-associated levels of a proinflammatory cytokine in a subject, a method for reducing microvessel density in fixed bowel tissue sections and a method for treating an inflammatory bowel disease are disclosed. Preferred agents to achieve the foregoing are pentapeptides that include Pro-His-Ser-Cys-Asn (SEQ ID NO:1) and variants or derivatives thereof. | 2009-12-17 |
20090312244 | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against | 2009-12-17 |
20090312245 | SRA binding protein - An isolated polypeptide comprising: (i) SEQ ID No: 2; (ii) amino acids 27 to 109 of SEQ ID No: 2 (iii) amino acids 22 to 109 of SEQ ID No: 2 (iv) amino acids 21-91 of SEQ ID No: 2 (v) amino acids 21-26 and/or 60-67 of SEQ ID No: 2 or (vi) a functional variant of any one of (i) to (v). | 2009-12-17 |
20090312246 | Uses of Glucoregulatory Proteins - The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases. | 2009-12-17 |
20090312247 | NATRIURETIC PEPTIDE RELATED FRAGMENT IN CARDIOVASCULAR DISEASE - This disclosure provides an intracellular fragment of natriuretic peptide receptor A (NPRA), referred to herein as soluble natriuretic peptide receptor-related fragment (sNRF). It is shown herein that sNRF causes NP resistance. Based on these observations, methods of treating a cardiovascular disorder by inhibiting the activity of sNRF are disclosed. Assays are provided that use sNRF to screen agents for their ability to increase the biological activity of an NPR, for example agents that increase the sensitivity of NPR for NPs (such as atrial natriuretic peptide, ANP), or that decrease growth factor deleterious effects, or combinations thereof. Also provided are agents identified using the disclosed assays, and methods of using the agents, for example to treat or diagnose a cardiovascular disorder, such as heart failure. | 2009-12-17 |
20090312248 | ANTIMICROBIAL PROTEIN - The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections. | 2009-12-17 |
20090312249 | TLR4 decoy receptor protein - The present application discloses a nucleic acid molecule encoding a fusion polypeptide capable of binding myeloid differentiation protein-2 (MD-2) polypeptide, which includes: a nucleotide sequence encoding an MD-2 polypeptide-binding portion of human toll-like receptor 4 (TLR4), a leucine-rich repeats (LRR) module, and a multimerizing component. | 2009-12-17 |
20090312250 | EPIDERMAL GROWTH FACTOR INCREASING INSULIN SECRETION AND LOWERING BLOOD GLUCOSE - The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes. | 2009-12-17 |
20090312251 | Methods of regulating differentiation in mammals - Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms with loss of expression of the differentiation regulator, and methods of preparing the transgenic organisms, are provided. | 2009-12-17 |
20090312252 | Antimicrobial Activity in Variants of Lacritin - The present invention provides recombinant proteins with antimicrobial activity and methods for treating animals including humans by administering the novel recombinant proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections using lacritin and homologs, fragments, modifications, and derivatives thereof. | 2009-12-17 |
20090312253 | Methods of effecting Wnt signaling through Dkk structural analysis - Compositions and methods related to Wnt signaling regulation by Dickkopf (Dkk) polypeptides and Wnt-related diseases are disclosed. For example, compounds that bind a Dkk or LRP polypeptide are disclosed. Compounds that disrupt binding of a Dkk polypeptide to an LRP polypeptide are also disclosed. Methods for using the described compounds and compositions are also disclosed. | 2009-12-17 |
20090312254 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2009-12-17 |
20090312255 | STIMULATION OF TRPV1+ SENSORY NEURONS TO CONTROL BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES - The present invention provides a method of altering the function of TRPV1+ sensory afferent neurons in the pancreas as a way of treating, managing, alleviating, etc., the symptoms and/or underlying causes of diabetes or abnormal glucose metabolism by increasing the release of neuropeptides, such as substance P (sP) or other tachykinin peptide, in the pancreas. This may be achieved by injecting a TRPV1 agonist, such as a capsaicinoid compound or capsaicin analog, or a neuropeptide, such as sP or other tachykinin peptide, directly into the pancreas, or alternatively, by stimulating one or more intercostal and/or subcostal nerves of spinal nerves derived from one or more thoracic segments T8 through T12 by chemical, electrical, surgical, mechanical, etc., methods. | 2009-12-17 |
20090312256 | USES OF HUMAN ZVEN PROTEINS AND POLYNUCLEOTIDES - The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. | 2009-12-17 |
20090312257 | USES OF HUMAN ZVEN PROTEINS AND POLYNUCLEOTIDES - The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. | 2009-12-17 |
20090312258 | USES OF HUMAN ZVEN PROTEINS AND POLYNUCLEOTIDES - The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. | 2009-12-17 |
20090312259 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS - This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus. | 2009-12-17 |
20090312260 | DRUG THERAPY FOR CELIAC SPRUE - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 2009-12-17 |
20090312261 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312262 | PEPTIDE COMPOUND WITH BIOLOGICAL ACTIVITY, ITS PREPARATION AND ITS APPLICATIONS - The invention relates to a peptide compound with biological activity, which in particular possesses antimicrobial properties, its preparation and its applications. | 2009-12-17 |
20090312263 | Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides - The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to methods of treating or preventing a disorder in a subject. The invention further relates to uses of C35 polypeptides in immunogenic compositions or vaccines, to induce antibody or T cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The present invention further relates to use of C35 polypeptides in diagnosing a pathological condition or susceptibility to a pathological condition in a subject. | 2009-12-17 |
20090312264 | Squamous Cell Carcinoma Antigen-Derived Peptide Binding to HLA-A24 Molecule - Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma. | 2009-12-17 |
20090312265 | NOVEL ANTIMICROBIAL PEPTIDES AND USE THEREOF - The invention relates to a molecule comprising at least the amino acid sequence K X K X | 2009-12-17 |
20090312266 | PEPTIDE DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 BINDING INTEGRIN ALPHA5BETA1 HAVING PROANGIOGENIC ACTIVITY - Description of a sequence peptide isolated in the domain II type-immunoglobulin (Type-Ig) of the Vascular Endothelial Growth Factor receptor 1 (VEGF-1) binding integrin α5β1, usable for the preparation of pharmacological agents having proangiogenic activity. | 2009-12-17 |
20090312267 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312268 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312269 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2009-12-17 |
20090312270 | Peptides having an ace inhibiting effect - Use of the tripeptide MAP optionally in combination with tripeptide ITP and salts thereof for the preparation of a functional food angiotensin-converting enzyme inhibitor. Also provided is the use of the tripeptide MAP and optionally the tripeptide ITP or salts thereof as an angiotensin-converting enzyme inhibitor in functional foods. | 2009-12-17 |
20090312271 | Method For Elevating Prolactin in Mammals - Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels. | 2009-12-17 |
20090312272 | Transglutaminase inhibitors and methods of use thereof - Transglutaminase inhibitors and methods of use thereof are provided. | 2009-12-17 |
20090312273 | Compositions compromising Dimethyl Sulfoxide (DMSO) - The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided. | 2009-12-17 |
20090312274 | Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases - Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis. | 2009-12-17 |
20090312275 | AGENT FOR IMPROVING INSULIN RESISTANCE - To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, or an organic solvent extract, a hot water extract or a squeezed liquid of a plant of the family Liliaceae or a fraction thereof which contains the compound as an active ingredient. | 2009-12-17 |
20090312276 | Compositions and Methods for Treating Cancer - Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 2009-12-17 |
20090312277 | Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent - The present invention provides a composition and method for increasing sensitivity of a cancer cell and to reverse or prevent resistance to a cytotoxic agent. The composition includes an inhibiting agent and, optionally, a cytotoxic agent. The inhibiting agent is present in a sub-lethal dose with respect to the cancer cell in the absence of the cytotoxic agent. | 2009-12-17 |
20090312278 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS - Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual the myeloablative bone marrow toxicities of chemotherapy. | 2009-12-17 |
20090312279 | Antimicrobial compositions - An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials. | 2009-12-17 |
20090312280 | COMBINATION THERAPY OF (2R,Z)-2-AMINO-2-CYCLOHEXYL-N-(5-(1-METHYL-1H-PYRAZOL-4-YL)-1-OXO-2,6-DIH- YDRO-1H-[1,2]DIAZEPINO[4,5,6-CD]INDOL-8-YL)ACETAMIDE - The present invention relates to novel combination therapies of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2,6-dihydro -1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide (compound 1), a pharmaceutically acceptable salt thereof, or a mixture thereof, in combination with an anti-cancer agent or radiation therapy. | 2009-12-17 |
20090312281 | PROCESS FOR THE PREPARATION OF A PULVERULENT COMPOSITION AND PRODUCT AS OBTAINED - Method of preparing a non-hygroscopic pulverulent composition, includes a step for the spray drying, without an atomization support, of an aqueous solution containing at least one initially hygroscopic product, having a glass transition temperature ranging from 10° C. to 110° C., and a cryogenic fluid, especially a food-grade cryogenic fluid, or a mixture of cryogenic fluids, particularly chosen from liquid air, nitrogen and carbon dioxide, the aqueous solution being obtained by dissolving the cryogenic fluid in an initial aqueous solution containing the initially hygroscopic product. | 2009-12-17 |
20090312282 | Novel Low Molecular Weight Hyaluronic Acid and/or Salt Thereof, and Cosmetic Preparation, Pharmaceutical Composition, and Food Composition Each Using Same - A low-molecular-weight hyaluronic acid and/or its salt has an average molecular weight of 5000 to 20,000, and has a molecular weight distribution in which the proportion of components having a molecular weight of 10,000 or less is 40 wt % or more and the proportion of components having a molecular weight of 50,000 or more is 5 wt % or less. | 2009-12-17 |
20090312283 | BRANCHED HYALURONIC ACID AND METHOD OF MANUFACTURE - A branched hyaluronic acid, wherein the linear backbone comprises hyaluronic acid in which one or more N-Acetyl-Glucosamine has been deacetylated to Glucosamine, with branching sidechain(s) covalently linked to the primary amine(s) of said deacetylated Glucosamine thus forming a secondary amine(s); a precursor for producing said branched hyaluronic acid; and a method for producing said branching hyaluronic acid | 2009-12-17 |
20090312284 | HISTONE DEACETYLASE INHIBITORS WITH COMBINED ACTIVITY ON CLASS-I AND CLASS-IIB HISTONE DEACETYLASES IN COMBINATION WITH PROTEASOME INHIBITORS - The present invention is concerned with combinations of a proteasome inhibitor and a histone deacetylase inhibitor with combined activity on class-I and class-IIb histone deacetylases, for inhibiting the growth of tumor cells, useful in the treatment of cancer. | 2009-12-17 |
20090312285 | BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM AND METHODS OF USE - Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis. | 2009-12-17 |
20090312286 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS - The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I) | 2009-12-17 |
20090312287 | MULTI-CAROTENOIDS COMPOSITIONS AND METHODS - A stable nutritional supplement composition for oral administration comprising, in one form, about 71% by weight, of a tomato extract containing therein at least 2% to 10% by weight of lycopene, 0.25% to 2% by weight of phytoene, and 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising .beta.-carotene, .gamma.-carotene, and .delta.-carotene, a phytosterol, a tocopheral and a phospholipid. The tomato extract may be further processed into oleoresin emulsions, or into beadlets, or into dry powders. Methods for ameliorating the effects of aging-related urinary tract malfunctions in men, comprising orally administrating on a regular basis, an effective amount of the nutritional supplement compositions disclosed herein. | 2009-12-17 |
20090312288 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 2009-12-17 |
20090312289 | IBANDRONATE POLYMORPH - The present invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formula | 2009-12-17 |
20090312290 | COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND IMATINIB FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA - The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, novembichin, phenesterine, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula | 2009-12-17 |
20090312291 | AGENT FOR PREVENTING INFECTION - An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a fat globule membrane component as an active ingredient. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a sphigosine-containing phospholipid and/or a derivative thereof, particularly sphingomyelin, as an active ingredient. | 2009-12-17 |
20090312292 | Peracetic Acid Composition - The invention relates to anti-microbial compositions useful against a wide range of microorganisms undesirable on a wide variety of materials, including food, food contact and non-food contact surfaces, and surfaces in industrial, recreational, health care, and other institutional environments. More particularly, the anti-microbial compositions comprise peracetic acid in combination with a) citric acid or a salt and b) salicylic acid or a salt in aqueous solution. | 2009-12-17 |
20090312293 | PROCESS FOR THE ISOLATION OF PHARMACOLOGICALLY ACTIVE PRINCIPLES OF VEGETABLE AND ANIMAL ORIGIN - A process for the recovery and purification of natural hydrophilic water-soluble products in conjugated form from vegetable aqueous extracts or physiological fluids, by adsorption of the extracts or fluids on a lipophilic resin, followed by desorption and recovery of the eluate, which process is characterized in that the resin is a porous styrene-divinyl benzene polymer brominated at the styrene and/or divinylbenzene portion, with 600 m | 2009-12-17 |
20090312294 | Method and Agent for Reducing Weight, Accelerating Lipid Catabolism, and/or Restricting Calories - A method and an agent for reducing weight, accelerating lipid catabolism, and/or restricting calories includes a preparation having chrysin and cholic acid for producing a medicament. | 2009-12-17 |
20090312295 | Second line treatment of metastatic hormone refractory prostate cancer using satraplatin - The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2 | 2009-12-17 |
20090312296 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES - The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis. | 2009-12-17 |
20090312297 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS - The invention provides compounds and pharmaceutical compositions that can be used to treat or prevent atherosclerosis, stroke, and other ischemic vascular diseases, dyslipidemia and hypercholestcrolemia and prevent complications of these conditions. Agents in accordance with the invention include; tauroursodeoxycholic acid (TUDCA), and analogs and derivatives thereof; 4-phenyl butyric acid (PBA), and analogs and derivatives thereof; and trimethyl N-oxide (TMAO), and analogs and derivatives thereof. | 2009-12-17 |
20090312298 | Methods and Compositions Related to GABA Receptor Subunits - Disclosed are compositions and methods related to GABA | 2009-12-17 |
20090312299 | Isolated Isomers of Norelgestromin and Methods of Making and Using the Same - The invention is directed to a process of preparing substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions. | 2009-12-17 |
20090312300 | NOVEL MACROCYCLIC PEPTIDES - Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus. | 2009-12-17 |
20090312301 | Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis - The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal. | 2009-12-17 |
20090312302 | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders - The invention relates to compositions containing cholesterol absorption inhibitors alone or in combination with other therapeutic agents for treating non-alcoholic fatty liver disease-associated disorders by administering a therapeutically effective amount of the compositions to a subject in need thereof. | 2009-12-17 |
20090312303 | Antidiabetic Bicyclic Compounds - Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 2009-12-17 |
20090312304 | ORGANIC COMPOUNDS - 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I, | 2009-12-17 |
20090312305 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR - A compound represented by the structural formula: | 2009-12-17 |
20090312306 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS - A compound of Formula I: | 2009-12-17 |
20090312307 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION - Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the K | 2009-12-17 |
20090312308 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS - The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. | 2009-12-17 |
20090312309 | Novel Medicaments - Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom. | 2009-12-17 |
20090312310 | Imidazothiazole derivatives - There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: | 2009-12-17 |
20090312311 | COMBINATION OF ORGANIC COMPOUNDS - The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases | 2009-12-17 |
20090312312 | Heterobicyclic Metalloprotease Inhibitors - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors. | 2009-12-17 |
20090312313 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: | 2009-12-17 |
20090312314 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS - The present invention is concerned with novel sulfonamides of formula | 2009-12-17 |
20090312315 | PAI-1 INHIBITOR - The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; | 2009-12-17 |
20090312316 | NOVEL COMPOUNDS - The present invention relates to derivatives of borrelidin that are useful in medicine, e.g. in the treatment of cancer or B-cell malignancies, or other diseases in which angiogenesis contributes to the pathology including ophthalmic disorders such as diabetic retinopathy as well as age related macular degeneration (AMD), corneal neovascularisation and retinopathy or prematurity. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies and other diseases in which angiogenesis is implicated in the pathogenic process. | 2009-12-17 |
20090312317 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER - Coumarin compounds of formula (I): | 2009-12-17 |
20090312318 | THERAPEUTIC COMPOUNDS AND METHODS - The present invention provides compounds of Formula (I): wherein A, X, Q, R | 2009-12-17 |
20090312319 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2009-12-17 |
20090312320 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF - Provided herein are Aminopurine Compounds having the following structure: | 2009-12-17 |
20090312321 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS - Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3β, IGF-1R, IKKα, IKKβ, IR, IRAK4, ITK, JAK2, JAK3, JNK1α1, JNK2α, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFRα, PDK1, Pim-2, Plk3, PKA, PKBα, PKCα, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70. | 2009-12-17 |
20090312322 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 - The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, [Chemical formula should be inserted here. Please see paper copy.] wherein R | 2009-12-17 |
20090312323 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES - Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift. | 2009-12-17 |